Therapeutic efficacy of infused molecular hydrogen in saline on rheumatoid arthritis: A randomized, double-blind, placebo-controlled pilot study

International Immunopharmacology

Volumn 21, Issue 2, 2014, Pages 468-473

  Ishibashi, Toru ^a   Sato, Bunpei ^b   Shibata, Shinji ^a   Sakai, Takaaki ^a   Hara, Yuichi ^a   Naritomi, Yuji ^a   Koyanagi, Samon ^a   Hara, Hiroshi ^a   Nagao, Tetsuhiko ^c  

^a Hara Doi Hospital   (Japan)

^b MiZ Company ^*  (Japan)

^c Midorino Clinic   (Japan)

Author keywords

IL 6; MMP 3; Molecular hydrogen; Reactive oxygen species; Rheumatoid arthritis

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; ANTIINFECTIVE AGENT; ANTIOXIDANT; BIOLOGICAL MARKER; C REACTIVE PROTEIN; HYDROGEN; INTERLEUKIN 6; MOLECULAR HYDROGEN SALINE; PLACEBO; SODIUM CHLORIDE; STROMELYSIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; 8-OXO-7-HYDRODEOXYGUANOSINE; DEOXYGUANOSINE;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DAS28; DISEASE ACTIVITY; DISEASE CONTROL; DISEASE DURATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INFUSION; DRUG SAFETY; ENZYME BLOOD LEVEL; FEMALE; HUMAN; MALE; PILOT STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; THERAPY EFFECT; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; ARTHRITIS, RHEUMATOID; DRUG EFFECTS; INFLAMMATION; JOINT; METABOLISM; MIDDLE AGED; URINE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ARTHRITIS, RHEUMATOID; DEOXYGUANOSINE; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYDROGEN; INFLAMMATION; INTERLEUKIN-6; JOINTS; MALE; MATRIX METALLOPROTEINASE 3; MIDDLE AGED; PILOT PROJECTS; SODIUM CHLORIDE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84903194951     PISSN: 15675769     EISSN: 18781705     Source Type: Journal    
DOI: 10.1016/j.intimp.2014.06.001     Document Type: Article

References (34)

1. I.B. McInnes, and G. Schett The pathogenesis of rheumatoid arthritis N Engl J Med 365 2011 2205 2219
2. H.S. Smith, A.R. Smith, and P. Seidner Painful rheumatoid arthritis Pain Physician 14 2011 E427 E458
3. T. Kishimoto IL-6: from its discovery to clinical applications Int Immunol 22 2010 347 352
4. M. Feldmann, F.M. Brennan, and R.N. Maini Rheumatoid arthritis Cell 85 1996 307 310
5. T. Ishibashi Molecular hydrogen: new antioxidant and anti-inflammatory therapy for rheumatoid arthritis and related diseases Curr Pharm Des 19 2013 6375 6381
6. K. Hadjigogos The role of free radicals in the pathogenesis of rheumatoid arthritis Panminerva Med 45 2003 7 13
7. P.G. Winyard, B. Ryan, P. Eggleton, A. Nissim, E. Taylor, and M.L. Lo Faro et al. Measurement and meaning of markers of reactive species of oxygen, nitrogen and sulfur in healthy human subjects and patients with inflammatory joint disease Biochem Soc Trans 39 2011 1226 1232
8. D.C. Phillips, H.K. Dias, G.D. Kitas, and H.R. Griffiths Aberrant reactive oxygen and nitrogen species generation in rheumatoid arthritis (RA): causes and consequences for immune function, cell survival, and therapeutic intervention Antioxid Redox Signal 12 2010 743 785
9. B. Gharib, S. Hanna, O.M. Abdallahi, H. Lepidi, B. Gardette, and M. De Reggi Anti-inflammatory properties of molecular hydrogen: investigation on parasite-induced liver inflammation C R Acad Sci III 324 2001 719 724
10. K. Ohno, M. Ito, M. Ichihara, and M. Ito Molecular hydrogen as an emerging therapeutic medical gas for neurodegenerative and other diseases Oxidative Med Cell Longev 2012 2012 353152
11. J.H. Abraini, M.C. Gardette-Chauffour, E. Martinez, J.C. Rostain, and C. Lemaire Psychophysiological reactions in humans during an open sea dive to 500 m with a hydrogen-helium-oxygen mixture J Appl Physiol 76 1994 1113 1118
12. P. Fontanari, M. Badier, C. Guillot, C. Tomei, H. Burnet, and B. Gardette et al. Changes in maximal performance of inspiratory and skeletal muscles during and after the 7.1-MPa Hydra 10 record human dive Eur J Appl Physiol 81 2000 325 328
13. H. Bjurstedt, and G. Severin The prevention of decompression sickness and nitrogen narcosis by the use of hydrogen as a substitute for nitrogen, the Arne Zetterstrôm method for deep-sea diving Mil Surg 103 1948 107 116
14. I. Ohsawa, M. Ishikawa, K. Takahashi, M. Watanabe, K. Nishimaki, and K. Yamagata et al. Hydrogen acts as a therapeutic antioxidant by selectively reducing cytotoxic oxygen radicals Nat Med 13 2007 688 694
15. S. Ohta Recent progress toward hydrogen medicine: potential of molecular hydrogen for preventive and therapeutic applications Curr Pharm Des 17 2011 2241 2252
16. T. Ishibashi, B. Sato, M. Rikitake, T. Seo, R. Kurokawa, and Y. Hara et al. Consumption of water containing a high concentration of molecular hydrogen reduces oxidative stress and disease activity in patients with rheumatoid arthritis: an open-label pilot study Med Gas Res 2 2012 27
17. K. Nagatani, H. Nawashiro, S. Takeuchi, S. Tomura, N. Otani, and H. Osada et al. Safety of intravenous administration of hydrogen-enriched fluid in patients with acute cerebral ischemia: initial clinical studies Med Gas Res 3 2013 13
18. H. Ono, Y. Nishijima, N. Adachi, S. Tachibana, S. Chitoku, and S. Mukaihara et al. Improved brain MRI indices in the acute brain stem infarct sites treated with hydroxyl radical scavengers, Edaravone and hydrogen, as compared to Edaravone alone. A non-controlled study Med Gas Res 1 2011 12
19. T. Seo, R. Kurokawa, and B. Sato A convenient method for determining the concentration of hydrogen in water: use of methylene blue with colloidal platinum Med Gas Res 2 2012 1
20. M.L. Prevoo, M.A. Van't Hof, H.H. Kuper, M.A. van Leeuwen, L.B. van de Putte, and P.L. van Riel Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis Arthritis Rheum 38 1995 44 48
21. D. Aletaha, T. Neogi, A.J. Silman, J. Funovits, D.T. Felson, and C.O. Bingham III et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative Ann Rheum Dis 69 2010 1580 1588
22. S. Yokota, T. Imagawa, M. Mori, T. Miyamae, Y. Aihara, and S. Takei et al. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial Lancet 371 2008 998 1006
23. H.G. Chen, K.L. Xie, H.Z. Han, W.N. Wang, D.Q. Liu, and G.L. Wang et al. Heme oxygenase-1 mediates the anti-inflammatory effect of molecular hydrogen in LPS-stimulated RAW 264.7 macrophages Int J Surg 11 2013 1060 1066
24. N. Nishina, Y. Kaneko, H. Kameda, M. Kuwana, and T. Takeuchi Reduction of plasma IL-6 but not TNF-α by methotrexate in patients with early rheumatoid arthritis: a potential biomarker for radiographic progression Clin Rheumatol 32 2013 1661 1666
25. E.C. Keystone Strategies to control disease in rheumatoid arthritis with tumor necrosis factor antagonists - an opportunity to improve outcomes Nat Clin Pract Rheumatol 2 2006 594 601
26. M. Puszczewicz, and C. Iwaszkiewicz Role of anti-citrullinated protein antibodies in diagnosis and prognosis of rheumatoid arthritis Arch Med Sci 7 2011 189 194
27. R. Klaasen, T. Cantaert, C.A. Wijbrandts, C. Teitsma, D.M. Gerlag, and T.A. Out et al. The value of rheumatoid factor and anti-citrullinated protein antibodies as predictors of response to infliximab in rheumatoid arthritis: an exploratory study Rheumatology (Oxford) 50 2011 1487 1493
28. 2) treatment for acute erythymatous skin diseases. A report of 4 patients with safety data and a non-controlled feasibility study with H2 concentration measurement on two volunteers Med Gas Res 2 2012 14
29. P. Dieppe Did Galen describe rheumatoid arthritis? Ann Rheum Dis 47 1988 84 85
30. P.L. Mottram Past, present and future drug treatment for rheumatoid arthritis and systemic lupus erythematosus Immunol Cell Biol 81 2003 350 353
31. M. Nissilä, H. Isomäki, K. Kaarela, P. Kiviniemi, J. Martio, and S. Sarna Prognosis of inflammatory joint diseases. A three-year follow-up study Scand J Rheumatol 12 1983 33 38
32. J.R. Ward Historical perspective on the use of methotrexate for the treatment of rheumatoid arthritis J Rheumatol Suppl 12 Suppl. 12 1985 3 6
33. T. Sokka, M. Envalds, and T. Pincus Treatment of rheumatoid arthritis: a global perspective on the use of antirheumatic drugs Mod Rheumatol 18 2008 228 239
34. M.J. Elliott, R.N. Maini, M. Feldmann, A. Long-Fox, P. Charles, and P. Katsikis et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha Arthritis Rheum 36 1993 1681 1690